Trial Profile
The study of algorithm for insulin dose after the change to insulin glargine U300 (LANTUS-XR) for type 2 diabetic patients with poor glucose control under insulin therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 May 2019
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ISLAND STUDY
- 15 May 2019 Status changed from recruiting to discontinued.
- 09 Nov 2016 New trial record